Page 3 - Complete Remission News Today

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Feb. 22, 2023 /PRNewswire/ -- Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children.

- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical...

Investegate announcements from F. Hoffmann-La Roche Ltd, FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma

Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab

Interim data from phase III HAVEN 7 study reinforce Hemlibra's efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors1New and updated data support use of Polivy in diffuse

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial...

KITE’S  CAR  T-CELL  THERAPY  TECARTUS®  (BREXUCABTAGENE  AUTOLEUCEL)  GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF  RELAPSED  OR  REFRACTORY  ACUTE  LYMPHOBLASTIC  LEUKAEMIA  (r/r ALL) -- Approval Marks Kite’...